CTLA4 and neoplasm: Tumor immunology is one of the hottest topics in cancer biology; advances in tumor immunology have contributed to remarkable success stories, as represented by immune checkpoint inhibitors (anti-CTLA4, anti-PD1, and anti-PD1L antibodies) and chimeric antigen receptor (CAR) expressing engineered T cells (CAR-T).